论文部分内容阅读
目的观察华蟾素注射液联合TACE治疗中晚期原发性肝癌的临床疗效。方法选择确诊为中晚期原发性肝癌患者78例,随机分为华蟾素联合治疗组和TACE单纯治疗组两组。结果联合组和对照组有效率差异无统计学意义,但华蟾素治疗组患者的生活质量明显高于单纯治疗组,而且12个月以上的生存率显著高于对照组;治疗3个周期后,联合组患者的各项实验室指标优于对照组,差异有统计学意义。结论 TACE联合华蟾素治疗肝癌可以减轻TACE对肝功能的损害程度,同时提高机体免疫功能,延长生存期,是中晚期肝癌一种较理想的治疗方法。
Objective To observe the clinical efficacy of cinobufagin injection combined with TACE in the treatment of advanced primary liver cancer. Methods Seventy-eight patients with advanced primary hepatocellular carcinoma (HCC) were selected and randomly divided into two groups: Cinobufotalin combined group and TACE group. Results There was no significant difference in the effective rate between the combined group and the control group, but the quality of life of the cinobufotalin treatment group was significantly higher than that of the simple treatment group, and the survival rate was significantly higher than that of the control group after 12 months; after 3 cycles , The combined group of patients with laboratory indicators better than the control group, the difference was statistically significant. Conclusion TACE combined with cinobufacini can reduce the degree of liver damage caused by TACE, improve immune function and prolong survival, which is an ideal treatment for advanced hepatocellular carcinoma.